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Background:  The release of paclitaxel from a stent with biostable polymer reduces the restenosis after a PCI. The persistence of polymer 
in the arterial wall could have negative long term effects, like stent thrombosis. We assessed the hypothesis that paclitaxel-eluting stents with 
biodegradable polymer (BDP) release could offer better results than paclitaxel-eluting stent with biostable polymer (BSP) release in novo PCIs.
Methods:  We studied all patients who consecutively underwent a PCI with paclitaxel-eluting stents between January 2007 and December 2008. 
Average follow up was 23 months. The end points were: death, myocardial infarction, stroke, new target lesion revascularization and need of coronary 
artery bypass graft surgery during the follow-up period.
Results:  110 patients were included in the paclitaxel-eluting stents with BSP release arm and 45 patients in paclitaxel-eluting stent with BDP 
release arm. During the follow-up there were 6 deaths in the first group and 3 in the other, all of which were non-cardiovascular in origin (6% versus 
7.8%, respectively, NS). There was no STEMI in either group. Restenosis was found in 7 patients in the first group and in 3 patients in the second 
group (6.3% versus 6.6%, respectively, NS). Progression of disease was observed in 5 patients of the first group and 2 of the second (4.5% versus 
4.4 %, respectively, NS). None of the studied patients underwent revascularization surgery. At the end, there were no incidents in 98 patients of the 
BSP release group and 40 patients BDP release group (89% versus 88%, respectively; NS).
Conclusions:  Based in our clinical analyses, paclitaxel-eluting stent with biodegradable polymer release provided a combined profile of safety 
and efficacy that was noninferior to paclitaxel-eluting stent with biostable polymer release, considering diameter and length.
